Cargando…
Development and Characterization of a Novel Peptide—Drug Conjugate with DM1 for Treatment of FGFR2-Positive Tumors
A maytansin derivative, DM1, is a promising therapeutic compound for treating tumors, but is also a highly poisonous substance with various side effects. For clinical expansion, we tried to develop novel peptide–drug conjugates (PDCs) with DM1. In the study, a one-bead one-compound (OBOC) platform w...
Autores principales: | Wang, Yayu, Li, Yadan, Cao, Jieqiong, Meng, Qilin, Li, Xiaocen, Zhang, Yibo, Lam, Kit S., Hong, An, Liu, Ruiwu, Chen, Xiaojia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389697/ https://www.ncbi.nlm.nih.gov/pubmed/34440055 http://dx.doi.org/10.3390/biomedicines9080849 |
Ejemplares similares
-
A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2
por: Zhang, Yibo, et al.
Publicado: (2020) -
Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
por: Su, Zijian, et al.
Publicado: (2023) -
Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis
por: Meng, Qilin, et al.
Publicado: (2023) -
FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling
por: Yang, Yiqi, et al.
Publicado: (2023) -
miR-671-5p Blocks The Progression Of Human Esophageal Squamous Cell Carcinoma By Suppressing FGFR2
por: Li, Xiaoyan, et al.
Publicado: (2019)